This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed/will be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed/will be assessed monthly using standardized psychometric instruments. The study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Morisky Medication Adherence Scale (MMAS)
Timeframe: To be obtained/will be obtained once a month for 12 months.
Multidimensional Scale of Perceived Social Support (MSPSS)
Timeframe: To be obtained/will be obtained once a month for 12 months.
Insight Assessment Scale (IAS)
Timeframe: To be obtained/will be obtained once a month for 12 months.
Addiction Profile Index Clinical-Practitioner Form (API-C)
Timeframe: To be obtained/will be obtained once a month for 12 months.
Positive and Negative Syndrome Scale (PANSS)
Timeframe: To be obtained/will be obtained once a month for 12 months.
Global Assessment Scale (GAS)
Timeframe: To be obtained/will be obtained once a month for 12 months.
Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist